Sector News

GSK sells meningitis vaccines to Pfizer

June 22, 2015
Life sciences
GlaxoSmithKline will sell its meningitis vaccines Nimenrix and Mencevax to Pfizer to satisfy regulatory conditions for its asset-swap deal with Novartis.
 
The European Commission and other antitrust regulators were concerned because GSK acquired two rival meningitis vaccines – Menveo and Bexsero – from Novartis as part of the deal, which could have given the company too much power in the market.
 
Nimenrix and Mencevax are older vaccines that had combined sales of £34 million last year. The total value of the transaction with Pfizer is £82 million.
 
“Adding these two innovative and complementary vaccines to our current portfolio will allow us to more completely respond to meningococcal disease outbreaks as well as proactively address a critical public health need – the prevention of meningococcal disease across all ages,” says Susan Silbermann, president of Pfizer Vaccines.
 
“Acquiring these quadrivalent vaccines will broaden our ability to address the burden of meningococcal meningitis – an uncommon but serious and sometimes fatal disease.”
 
Last year Pfizer purchased another meningitis vaccine, Baxter’s NeisVac-C, and had its own serogroup B meningococcal disease drug Trumenba approved.
 
The sale is expected to be completed by the end of the year.
 
By George Underwood
 
Source: Pharma Times

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach